Gaby Danan,
MD, PhD

Dr. Danan is board qualified in Hepatology and Internal Medicine, and has conducted studies on drug hepatotoxicity and drug-drug interactions, and authored papers on pharmacovigilance definitions and methodologies. He joined the pharmaceutical industry in 1984 and, until his 2010 retirement, was the European Union Qualified Person for Pharmacovigilance for Sanofi. He has served as a member of the Council for International Organizations of Medical Sciences and International Council on Harmonisation Expert Working Groups, especially as the European Federation of Pharmaceutical Industries and Associations Clinical Safety topic leader of E2B. In 1993, he co-published the Roussel Uclaf Causality Assessment Method for drug-induced liver injury. He was elected to the DIA Board of Directors in 2001 and 2004, and chaired the 2010 DIA Annual Meeting. Dr. Danan co-chaired, with the European Medicines Agency, the EudraVigilance Expert Working Group from its inception until 2009. He continues to serve as a pharmacovigilance and risk assessment consultant and as member of the DIA Content Committee for Europe, Middle East, and Africa.